The Chinese-German Journal of Clinical Oncology

, Volume 8, Issue 12, pp 729–733

The application of Meta-analysis in the latest comprehensive treatment of breast cancer



Meta-analysis is a kind of systematic review, which uses quantitative method to summarize the results. It is a comprehensive evaluation to the findings of previous studies with higher credibility. Recently, it is applied to all areas of scientific research, particularly in the integrated treatment of breast cancer. Currently, breast cancer is known one of the most common malignant tumors, and its incidence is increasing year by year. Therefore, more and more clinical doctors pay attention to the effect of comprehensive treatment for patients with breast cancer. This article mainly collects the results of comprehensive treatment of breast cancer, in which the method of Meta-analysis is applied. In addition, we discuss the latest progress in order to guide the clinical treatment.

Key words

Meta-analysis breast cancer comprehensive treatment 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Moller JF, Nikolajsen L, Rodt SA, et al. Thoracic paravertebral block for breast cancer surgery: a randomized double-blind study. Anesth Analg, 2007, 105: 1848–1851.CrossRefPubMedGoogle Scholar
  2. 2.
    Montgomery GH, Bovbjerg DH, Schnur JB, et al. A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients. J Natl Cancer Inst, 2007, 99: 1304–1312.CrossRefPubMedGoogle Scholar
  3. 3.
    Sahoo S, Talwalkar SS, Martin AW, et al. Pathologic evaluation of cryoprobe-assisted lumpectomy for breast cancer. Am J Clin Pathol, 2007, 128: 239–244.CrossRefPubMedGoogle Scholar
  4. 4.
    Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: cochrane review. Br J Cancer, 2007, 96: 1025–1029.CrossRefPubMedGoogle Scholar
  5. 5.
    START Trialists’ Group, Bentzen SM, Agrawal RK, et al. The UK standardisation of breast radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet Oncol, 2008, 9: 331–341.CrossRefPubMedGoogle Scholar
  6. 6.
    Utehina O, Popovs S, Purina D, et al. Analysis of cardiac and pulmonary complication probabilities after radiation therapy for patients with early-stage breast cancer. Medicina, 2009, 45: 276–285.PubMedGoogle Scholar
  7. 7.
    Hwang JH, Chang HJ, Shim YH, et al. Effects of supervised exercise therapy in patients receiving radiotherapy for breast cancer. Yonsei Med J, 2008, 49: 443–450.CrossRefPubMedGoogle Scholar
  8. 8.
    Prescott RJ, Kunkler IH, Williams LJ, et al. A randomized controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population: the PRIME trial. Health Technol Assess, 2007, 11: 1–149.PubMedGoogle Scholar
  9. 9.
    Loibl S, von Minckwitz G, Harbeck N, et al. Clinical feasibility of (neo) adjuvant taxane-based chemotherapy in older patients: analysis of > 4500 patients from four German randomized breast cancer trials. Breast Cancer Res, 2008, 10: R77.CrossRefPubMedGoogle Scholar
  10. 10.
    Cuppone F, Bria E, Carlini P, et al. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer, 2008, 113: 238–246.CrossRefPubMedGoogle Scholar
  11. 11.
    Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res, 2007, 13: 228–233.CrossRefPubMedGoogle Scholar
  12. 12.
    von Minckwitz G, Kümmel S, Vogel P, et al. Intensified neoadjuvant hemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst, 2008, 100: 552–562.CrossRefGoogle Scholar
  13. 13.
    Ellis P, Barrett-Lee P, Johnson L, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomized controlled trial. Lancet, 2009, 373:1681–1692.CrossRefPubMedGoogle Scholar
  14. 14.
    Martín M, Rodríguez-Lescure A, Ruiz A, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst, 2008, 100: 805–814.CrossRefPubMedGoogle Scholar
  15. 15.
    Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med, 2008, 358: 1663–1671.CrossRefPubMedGoogle Scholar
  16. 16.
    Lechleider RJ, Kaminskas E, Jiang X, et al. Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies. Clin Cancer Res, 2008, 14: 4378–4384.CrossRefPubMedGoogle Scholar
  17. 17.
    Rivera E, Mejia JA, Arun BK, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer, 2008, 112: 1455–1461.CrossRefPubMedGoogle Scholar
  18. 18.
    Fountzilas G, Dafni U, Gogas H, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol, 2008, 19: 853–860.CrossRefPubMedGoogle Scholar
  19. 19.
    Mouridsen HT. Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat, 2007, 105: 19–29.CrossRefPubMedGoogle Scholar
  20. 20.
    Chiesa MD, Passalacqua R, Michiara M, et al. Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomized multicentre trial. Acta Biomed, 2007, 78: 204–209.PubMedGoogle Scholar
  21. 21.
    Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat, 2007, 105: 33–43.CrossRefPubMedGoogle Scholar
  22. 22.
    Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst, 2007, 99: 1845–1853.CrossRefPubMedGoogle Scholar
  23. 23.
    Guarneri V, Frassoldati A, Bruzzi P, et al. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2-positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer, 2008, 8: 453–456.CrossRefPubMedGoogle Scholar
  24. 24.
    Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol, 2008, 19: 1090–1096.CrossRefPubMedGoogle Scholar
  25. 25.
    Viani GA, Afonso SL, Stefano EJ, et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer, 2007, 7: 153.CrossRefPubMedGoogle Scholar
  26. 26.
    Dahabreh IJ, Linardou H, Siannis F, et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist, 2008, 13: 620–630.CrossRefPubMedGoogle Scholar
  27. 27.
    Ryan Q, Ibrahim A, Cohen MH, et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist, 2008, 13: 1114–1119.CrossRefPubMedGoogle Scholar
  28. 28.
    Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 2007, 357: 2666–2676.CrossRefPubMedGoogle Scholar
  29. 29.
    Zhang WB, Wang B, Shi LC. The application of traditional Chinese medical in the modern breast cancer treatment. Chin J Integr Tradit West Med Intens Crit Care (Chinese), 2002, 1: 54–55.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.Department of OncologyThe General Hospital of Shenyang Military RegionShenyangChina
  2. 2.Liaoning University of Traditional Chinese MedicineShenyangChina

Personalised recommendations